Bavituximab

• Description :

  Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS) -targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].

• Product Name Alternative :

  Anti-Human Phosphatidylserine Recombinant Antibody

• UNSPSC :

  12352203

• Target :

  Others

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bavituximab.html

• Purity :

  97.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Bavituximab]

• Molecular Weight :

  (145.336 kDa)

• References & Citations :

  [1]Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86 (2) :231-6. |[2]Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23 (Suppl 5) :583-591.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [648904-28-3]